We have started our all modern Radiotherapy, PET CT and Nuclear Medicine division with affordable cost in our new hospital at Nayabad, Garia. Open 24x7 for 365 days. Contact no. 033-24320043/39, 9874210007/05
Joomla Templates and Joomla Extensions by JoomlaVision.Com

Quick Contact

Name :

Email :

Phone :

Massage :


Clinical Research


  • Clinical Research / Clinical Drug Trial :

Principal Investigator (PI), Co-Investigator with Clinical Research Co coordinator( CRC) are doing the clinical Trial on Cancer as follows :

  • Completed Study as on 16 March 2011 :


STUDY TITLE: An Open Label, Multicenter Phase I/II study on Relapsed and/or Relapsed/Refractory Multiple Myeloma.


STUDY TITLE: A Phase III Clinical Study Relapse in Lymphoma .


STUDY TITLE: A multicenter, randomized, open label steady state, in patients with Acute Lymphocytic Leukemia who are already stabilized on Mercaptopurine therapy in male/female under fasting conditions.


STUDY TITLE: A Randomized, Open Label, Two Treatment, Two Sequence, Steady-State Crossover Bioequivalence Study of Imatinib Mesylate 400 mg and Gleevec (Imatinib Mesylate) 400mg Tablets, Administered Under Fed (Normal Meal) Conditions in a Stable Regimen for 3 Months.


STUDY TITLE: FM CL 2 – Phase 1b Single Arm in Relapsed or Relapsed-and-Refractory Multiple Myeloma. .




STUDY TITLE: An Open Label, Balanced, Randomized, in Advanced Solid Tumor Patients”


STUDY TITLE: A multicentre, randomized, open label, two-period, in patients of Locally Advanced or Metastatic Breast Cancer or Metastatic Colorectal Cancer.


STUDY TITLE: A Phase II study of Mycobacterium in Advanced Non Small Cell Lung Cancer


STUDY TITLE: A multinational, randomized, double-blind in the Prevention of Venous Thromboembolism (VTE) in cancer patients at high risk for VTE.


STUDY TITLE: An International Randomized, Double Blind, Phase 3 with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer

Ongoing Study’s

As on 16 March 2011


I. STUDY TITLE: A Randomised, Multi-Centre, Open Label, Phase III study in patients with HER2/ErbB2 positive primary Breast Cancer

II. STUDY TITLE: A Randomised, Open Label, Multicentre Phase 3 with Newly Diagnosed Mantle Cell Lymphoma who are not Eligible for a Bone Marrow Transplant .

III. STUDY TITLE: A Multicentric open label Phase III study to evaluate the safety and efficacy of Rituximab (Zenotech) in patients with relapsed or refractory low grade or follicular Non Hodgkin’s Lymphoma. (Study Code: Zen-01/2006).

IV. STUDY TITLE: A Randomized Double-Blind Phase 3 Trial Comparing in Castration-Resistant Prostate Cancer.

V. STUDY TITLE: Open Label, Randomised, Multicentric Clinical trial in Metastatic Hormone Refractory Prostate Cancer

VI. STUDY TITLE: Phase II single-arm study of patients with recurring platinum-resistant ovarian cancer

VII. STUDY TITLE: A multi-center, prospective, open-label, clinical trial in patients with idiopathic (immune) thrombocytopenic purpura.

VIII. STUDY TITLE: A Randomized, Double-blind, Placebo-controlled Study With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.

IX. STUDY TITLE: An Open Label, Balanced, Randomized, Multicentre, in Adult Subjects with Acute Lymphoblastic Leukemia

X. STUDY TITLE: A Phase 2, Randomized, Double-blind, KRAS – mutant Metastatic Colorectal Carcinoma.

XI. STUDY TITLE: A Randomized, Multicentre, Open-label, Phase 3 Wild-type KRAS, Metastatic Colorectal Cancer

XII . STUDY TITLE: LUX-Breast 1: An open label, randomized phase III with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment”